Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males

CONTEXT: TAK-385 is a highly selective, oral, nonpeptide GnRH antagonist being investigated as a possible prostate cancer treatment. OBJECTIVE: The objectives were to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-385 on LH and testosterone. DESIGN, SETTING, AND PARTICI...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Clin Endocrinol Metab
Hlavní autoři: MacLean, David B., Shi, Hongliang, Faessel, Hélène M., Saad, Fred
Médium: Artigo
Jazyk:Inglês
Vydáno: Endocrine Society 2015
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4667159/
https://ncbi.nlm.nih.gov/pubmed/26502357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2015-2770
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky